Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation

Sacubitril/valsartan (SAC/VAL), an angiotensin receptor blocker-neprilysin inhibitor, has been widely used to treat several types of heart failure. Nevertheless, the effects of drugs in mitral regurgitation patients, from the molecular level to therapeutic effects, remain unclear. This study investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantisuwat, Lalida, Saengklub, Nakkawee, Boonpala, Pakit, Kumphune, Sarawut, Panyasing, Yaowalak, Kalandakanond-Thongsong, Sarinee, Kijtawornrat, Anusak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350457/
https://www.ncbi.nlm.nih.gov/pubmed/37455281
http://dx.doi.org/10.1038/s41598-023-38694-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350457/
https://www.ncbi.nlm.nih.gov/pubmed/37455281
http://dx.doi.org/10.1038/s41598-023-38694-6

Ejemplares similares